B
cl-3 is a member of the IkB family, which is distinguished by shared ankyrin repeat domains capable of interacting with the Rel homology domains present in NF-kB transcription factors. Whereas the classical members IkBa, IkBb, and IkBε primarily retain, and thus inhibit, p65-and c-Rel-containing NF-kB dimers in the cytoplasm, Bcl-3 instead associates with nuclear p50 or p52 homodimers bound to DNA. Depending on the cellular context and target gene, Bcl-3 may promote or suppress transcription of certain NF-kB-regulated genes (1, 2) . However, the specific biologic functions and mechanisms of action of Bcl-3 in cells remain poorly understood.
Nevertheless, Bcl-3 can have profound biological impact in vivo. The bcl3 gene was first identified and cloned at the breakpoint of recurring chromosomal translocations t (14;19) in B cell chronic lymphocytic leukemias (3) . Subsequently, additional translocations of the bcl3 were discovered in other B and some T cell tumors, resulting in increased and deregulated expression of otherwise unchanged Bcl-3 (4-7). High levels of nuclear Bcl-3 have also been detected in a variety of B cell tumors in the absence of translocations, including classic Hodgkin's lymphomas (8) (9) (10) . In addition, a number of solid tumors express high levels of Bcl-3 (11) .
It has been suggested that Bcl-3 may contribute to the survival and/or proliferation of tumor cells by positively regulating the expression of proteins such as Cyclin D1 and Hdm-2 (12) (13) (14) . However, these and other reports implicating possible targets of Bcl-3 in tumors remain isolated accounts, and how Bcl-3 actually promotes tumor formation is still an open question. Adding to this uncertainty, Bcl-3 has been suggested to intrinsically slow rather than promote proliferation of nontumorigenic T cells (15) , to contribute to apoptosis in some tumor lines (16, 17) , and, in distinction to earlier views, may not have a role in survival of activated CD8 T cells in vivo (18) .
Apart from its tumorigenic potential, Bcl-3 is critical in host defense against certain pathogens, makes contributions to immune development, and can suppress autoimmunity (19) (20) (21) (22) (23) (24) . However, the mechanisms underlying these in vivo roles also remain obscure. In vitro, Bcl-3 negatively regulates LPS-induced expression of some chemokines and cytokines in macrophages and dendritic cells. The proposed mechanism envisions Bcl-3 to aid p50 homodimer-mediated transcriptional inhibition (22, 25, 26) by preventing ubiquitin-mediated degradation of the homodimers (27) . However, it remains to be determined whether this is the only or even primary mechanism by which Bcl-3 inhibits, and it leaves open the question when and how Bcl-3 promotes transcription. In this regard, it is important to note that the functional activities of Bcl-3 may be controlled not only by its inducible expression (16, 25, 28, 29) , but also by posttranslational means, including phosphorylation and ubiquitination (30) (31) (32) (33) (34) .
Based on such findings, Bcl-3 appears to have diverse cell-, signal-, and gene-specific effects, and how it operates in specific biologic contexts largely remains to be discovered. Despite its oncogenic potential in B cells, Bcl-3's role in normal B cells has not been addressed. Surprisingly, we find in this study that Bcl-3 delimits the development of marginal zone (MZ) B cells, favoring development of follicular (FO) B cells instead. Bcl-3 promotes survival and thus overall proliferation of cells stimulated via their BCR, whereas it impairs responses to LPS. We will discuss how these activities may be relevant to the cell fate decision of developing B cells, as well as the tumorigenic potential of Bcl-3.
Materials and Methods

Mice
Bcl-3 knockout (KO) mice have been described previously (19) . Bcl-3 transgenic (Tg) mice with mb-1-Cre-driven, B cell-specific expression of the transgene are described in the supplemental materials. These mice were bred and cohoused together with genetically matched C57BL/6 wildtype (WT) controls in National Institute of Allergy and Infectious Diseases Institute facilities. They were analyzed at 6-8 wk of age, and all experiments were done with approval of the National Institute of Allergy and Infectious Diseases Animal Care and Use Committee and in accordance with all relevant institutional guidelines. 
Antibodies
Cell purification
Total B cells were purified from erythrocyte-lysed single-cell suspensions of splenocytes by negative selection with anti-CD43 microbeads on midi MACS columns or by AutoMACS (Miltenyi Biotec), according to the manufacturer's instructions. For isolation of MZ B and FO B cell subsets, purified total B cells pooled from four to five mice were incubated with FcRblocking Ab 2.4G2, stained with allophycocyanin-anti-CD21, PE-anti-CD23, allophycocyanin-Cy7-anti-B220, PE-Cy7-anti-AA4. 
Flow cytometry
FACS analyses were performed on freshly prepared splenocytes (in PBS/ 0.5% BSA/2 mM EDTA) or on cultured flow-or bead-sorted B cell subsets (see earlier). For surface marker staining, cells were preincubated with anti-FcgRIII/II for 10 min on ice and then stained with conjugated Abs for 30 min. The LIVE/DEAD Fixable Aqua Dead cell stain kit (Invitrogen) was used for live cell gating. Staining was analyzed on a FACSCalibur or Canto II (BD Biosciences). Data were analyzed with FlowJo software.
Bone marrow chimeras
Bone marrow cells were harvested by flushing femurs and tibias of mice with cold HBSS. A total of 3-5 3 10 6 erythrocyte-lysed bone marrow cells were injected into the tail veins of lethally irradiated (900 rad) recipient mice in 0.2 ml HBSS, and recipient mice were analyzed 6-8 wk after transfer.
Cell culture and proliferation and caspase 3 assays 
Immunofluorescence
Spleens were embedded in OCT and frozen. Cryostat sections were fixed for 10 min in ice-cold acetone and sequentially blocked with blocking buffer containing 10% rabbit or goat serum. Sections were washed in 50 mM TBS, pH 7.6, or PBS between all steps. Sections were incubated sequentially with rat anti-mouse MAdCAM (4˚C overnight) (detected with Alexa Fluor 568 anti-rat IgG) and then biotin-conjugated anti-CD1d at room temperature for 2 h followed with streptavidin-conjugated Alexa Fluor 647. Sections were examined using a Leica AF6000X fluorescence microscope, and images were acquired with a Hamamatsu video camera and processed with Imaris software.
Statistical analysis
Data were recorded as the mean 6 SEM for direct ex vivo experiments and the mean 6 SD for in vitro culture experiments. Results were analyzed using Student t tests. A p value ,0.05 was considered significant. 2C ; enumerated in Fig. 2D ). Together, these results indicate that the increase in MZ B cells and reduction in FO B cells in Bcl-3-deficient mice were due to B cell-intrinsic and cell-autonomous defects. Fig. 1A, 1B) .
Results
Bcl
Modulation of integrin levels in Bcl-3 2/2 B cells
Several signals have been proposed to positively impact whether transitional B cells become MZ B cells and then are maintained as such (42) . This includes Notch2 signals (43) and a preference to respond to S1P over CXCL13, agents that direct the egress and entry of B cells into follicles, respectively (44). We did not find any evidence that Bcl-3 is involved in the Notch2 pathway, as expression of the target gene Deltex1 was not changed by the absence of Bcl-3 in FO or MZ B cells; similarly, in initial experiments, we failed to observe skewed chemotaxis of Bcl-3-deficient FO or MZ B cells toward S1P over CXCL13 (data not shown). BAFF-induced activation of the alternative NF-kB pathway is another signal critical for MZ B cell development (45) . Loss of Bcl-3 did not alter activation of this signaling pathway (Supplemental Fig. 2 ), although this does not rule out possible effects of Bcl-3 on target genes of alternatively activated NF-kB. MZ B cells express somewhat higher levels of the integrins LFA1 (aL/b2) and VLA4 (a4b1) than FO B cells; these integrins are thought to contribute to the long-term retention in the splenic MZ (46) . We observed a modest increase in the expression of aL and b2, and a slight increase in b1, although not a4, in both Bcl-3 2/2 FO and MZ freshly isolated B cells when compared with their WT counterparts (Fig. 3B, Supplemental Fig. 1C ). Slightly increased levels of, in particular, LFA1 in Bcl-3 2/2 B cells may therefore favor retention in the MZ and could contribute modestly to increased levels of MZ B cells. However, overall, these findings suggest that Bcl-3 likely regulates additional steps to control the process whereby B cells are fated to become either MZ or FO B cells.
Tg overexpression of Bcl-3 suppresses development of MZ B cells
To confirm and further explore the role of Bcl-3 in MZ versus FO B cell development, we generated mice in which expression of a Bcl-3 transgene could be induced specifically in B cells via Fig. 3A-C) . B cell-specific expression of the Bcl-3 transgene resulted in reduced relative and absolute numbers of MZ B cells when compared with WT, and especially when compared with KO B cells ( Fig. 4A-C Fig. 4C) . Nevertheless, consistent with the substantial relative decrease of MZ B cells in Tg B cells as determined with surface markers, immunofluorescence analysis showed a relative paucity of B cells in the MZ (Supplemental Fig. 3D) . Thus, B cell-specific overexpression of Bcl-3 appears to have largely, although not entirely, opposite effects to the loss of Bcl-3. These results further confirm that Bcl-3 negatively impacts MZ B cell generation, whereas promoting generation of FO B cells.
Bcl-3 differentially modulates aIgM-versus LPS-induced B cell proliferation
It has been hypothesized that very weak BCR signaling pushes developing B cells toward the MZ B cell fate, whereas relatively stronger BCR signaling (by self-Ag) favors the FO B cell fate (42, 48) . We FACS-sorted MZ B and FO B cells from B cells pooled from four to five mice and examined their proliferative responses counterparts (Fig. 5A) , despite similar levels of surface IgM (data not shown). We confirmed this by examining BrdU incorporation in aIgM-stimulated, bead-isolated FO B cells, gating on live cells (Fig. 5B ). In addition, we examined aIgM-and LPS-driven proliferation of CFSE-labeled, FACS-sorted FO and MZ B cells, respectively; in each instance, we compared WT, Bcl-3
2/2
, and Bcl-3 Tg B cells after 72 h of stimulation, gating on live cells ( Fig. 5C ; summary data shown as proliferation and division indices in Fig.  5D ). Bcl-3 2/2 MZ B cells again showed significantly increased LPS-induced proliferation over WT B cells, with Bcl-3 Tg MZ B cells proliferating similar to or slightly less well than WT (Fig.  5C, 5D , upper panels). In contrast, Bcl-3 2/2 FO B cells proliferated less well upon aIgM stimulation than their WT counterparts, consistent with earlier findings (Fig. 5C, 5D , lower panels). Bcl-3 Tg FO B cells also proliferated slightly less well than WT, albeit not significantly so, which indicated that Tg overexpression of Bcl-3 did not result in the exact opposite of the Bcl-3-deficient phenotype. Of note, aIgM stimulation of Bcl-3 2/2 FO B cells showed a significant decrease relative to WT in the division index, but only a trend in that direction in the proliferation index. This suggested the possibility that Bcl-3 2/2 FO B cells were more susceptible to apoptosis after aIgM stimulation, or else less responsive.
To investigate whether the absence of Bcl-3 in FO B cells might increase their rate of apoptosis upon BCR stimulation, we measured caspase 3 activation in bead-isolated FO B cells from WT, Bcl-3 and Tg mice after 48 h of stimulation with aIgM, LPS, or no stimulation, gating on live cells. BCR stimulation activated more caspase 3 than LPS across all three genotypes. Importantly, caspase 3 activation was significantly more prominent in BCR-stimulated Bcl-3 2/2 FO B compared with their WT counterparts, whereas
Bcl-3 Tg cells exhibited slightly lower levels than WT cells (Fig. 5E ). Bcl-3 may thus help protect FO B cells, in particular, from BCRinduced apoptosis, and this likely contributed to the lower level of apparent proliferation observed earlier in the absence of Bcl-3. We also assayed aIgM-and LPS-induced expression of select genes in FACS-sorted FO B cells and found a trend toward lower expression of proliferation-related genes in BCR-stimulated Bcl-3
FO B cells and a trend toward higher expression of antiapoptotic genes and IL-10 upon LPS stimulation of these mutant cells, consistent with generally diminished proliferative responses to aIgM and increased responses to LPS (Supplemental Fig. 4 ).
Discussion
In this article, we report that Bcl-3 controls the relative proportion of mature MZ B and FO B cells that are generated during splenic B cell development. This atypical member of the IkB family acted as a gatekeeper for the MZ B cell lineage; it delimited the number of MZ B cells, apparently exerting its influence during the time when developing B cells transition into and establish themselves as mature FO or MZ B cells. Although many proteins have been found to positively contribute to, or even be required for, MZ B cell development, including, in particular, NF-kB factors (42, 48, 49) , Bcl-3 is unusual because it negatively impacted this process. Bcl-3 restricted maturation of MZ B cells and, conversely, appeared to favor maturation of FO B cells; Bcl-3 may have had similar effects during the maintenance phase of these cells. The findings are based on analyses of mice lacking Bcl-3 or overexpressing Bcl-3 in B cells: loss of Bcl-3 resulted in a significantly higher proportion of MZ B cells and their immediate precursors, whereas it led to a reduction in the proportion of FO B cells, a phenomenon we showed to be intrinsic and autonomous to B cells. Conversely, Tg overexpression of Bcl-3 in B cells reduced relative numbers of MZ B cells when compared with WT, whereas it increased those of FO B cells. Analyses of splenic tissue sections furthermore revealed more B cells in the splenic MZ of Bcl-3-deficient mice and fewer in Bcl-3 Tg mice relative to WT mice, which confirmed the conclusions based on cell-surface marker expression. Potential mechanisms for how Bcl-3 so profoundly impacted B cell maturation were suggested by the findings that Bcl-3-deficient B cells exhibited impaired survival and, likely in consequence, impaired proliferation after BCR stimulation, whereas these cells exhibited increased responses to LPS, including increased proliferation.
MZ and FO B cells are thought to derive primarily from transitional T2 B cells in the spleen. How the decision is made which cell type to develop into is not really understood, but current theory postulates that BCR signaling strength may be the deciding factor (43) : In this model, B cells carrying BCRs that recognize self-Ags quite well, albeit not too strongly, are destined to become FO B cells, and in the process also become impervious to other signals, such as those delivered via Notch2. Such BCR signals may also help maintain these cells. By contrast, B cells carrying BCRs that recognize self-Ags only quite weakly are postulated to set out along the MZ B cell path; these cells remain receptive to and require other signals for full development, localization to, and retention in the MZ of the spleen, events that may be linked. Such additional signals include inputs via Notch2, BAFF receptors, integrins, chemokine receptors, and likely others (36, 48) . How a gradient in BCR signaling strength may be read out is not known but may involve NF-kB (42, 48) .
Our findings may be incorporated into this presently held model of splenic B cell development. We hypothesize that Bcl-3 may promote FO B cell development (and possibly also maintenance) over that of MZ B cells by strengthening BCR-mediated proliferation, at least in part, by promoting survival of these sostimulated cells. B cells recognizing self-Ags in vivo may thus be helped by Bcl-3 on their way to become FO B cells. Conversely, we hypothesize that Bcl-3 may inhibit MZ B cell development by dampening responses to signals that may promote the development (and possibly also maintenance) of these cells; such signals may include TLR signals, which are most likely encountered in the MZ. Loss of Bcl-3 leads to LPS hyperresponsiveness not only in B cells, but also in macrophages, where Bcl-3 has been postulated to aid p50-homodimer-dependent suppression of NFkB target genes (26, 27) . Interestingly, p50/NF-kB1 is required for MZ B cell development, opposite the role of Bcl-3 revealed in this study (42) . However, p50 is also a subunit of several trans-activating NF-kB heterodimers that are necessary for MZ B cell development. The differential in vitro effects of Bcl-3 on BCR-versus LPS-induced proliferation may appear to be modest, but when integrated over time in vivo could well explain the ultimate relative differences in numbers of FO and MZ B cells. Future experiments will be needed to prove this hypothesis.
Bcl-3 supported the survival of B cells especially after BCR stimulation. In the absence of Bcl-3, BCR stimulation of freshly isolated FO B cells led to significantly increased activation of caspase 3 and, likely as a consequence, reduced proliferation; conversely, there was trend toward reduced caspase 3 activation in Bcl-3 Tg FO B cells. Therefore, deregulated expression of Bcl-3 in consequence of gene translocation may contribute to malignant transformation by promoting survival in the face of such stimuli, although proof will have to await future investigations. Nevertheless, Tg overexpression of Bcl-3 increased not only the proportion of FO B cells, but also total numbers of B cells in spleens.
Bcl-3 may have affected the ultimate ratio of MZ to FO B cells by exerting its influence as early as the time when the cell fate decision is made; this is suggested by the observed trend toward increased numbers of MZPs and FO type II cells in the absence of Bcl-3. FO II B cells are a small fraction of FO B cells that is thought to have experienced little/no self-Ag stimulation and that may serve as a reservoir for MZ B cells in follicles (42) . FO II cells are thus more akin to MZ B cells and their precursors. Of note, Tg expression of Bcl-3 resulted in population shifts that were largely opposite those seen in the absence of Bcl-3: the proportion of FO I B cells was increased and that of MZ B cells was reduced. However, relative numbers of MZP and FO II B cells were not significantly changed; the reason for this is not clear, although overexpression of Bcl-3 may not necessarily always accentuate normal functions, especially when these functions may also be regulated by posttranslational modifications. Indeed, we did not observe significant differences in Bcl-3 mRNA expression in the various splenic subpopulations (data not shown), which suggests that Bcl-3 might also be regulated by means other than just its levels of expression.
MZ B cells play important innate roles in host defense; they respond better to LPS and express generally higher levels of costimulatory molecules than FO B cells (49) . Consistent with this, we observed higher titers of IgM after LPS challenge in the serum of Bcl-3-deficient mice compared with controls (data not shown). LPS-stimulated Bcl-3 2 /2 FO and MZ B cells also expressed higher levels of some costimulatory molecules, and mutant B cells were better able to costimulate T cells. Furthermore, mutant FO and MZ B cells expressed slightly higher levels of an integrin thought to help retention of MZ B cells, and they proliferated slightly better to LPS stimulation. These data suggest that loss of Bcl-3 shifts B cells toward MZ B cell-associated phenotypes. Conversely, the presence of Bcl-3 appears to dampen innate and promote adaptive responses to an immune challenge. We have shown that Bcl-3 skews B cells toward the FO B cell fate and away from the MZ B fate, thus acting as a gatekeeper for MZ B cell development. Bcl-3 limits apoptosis associated, in particular, with BCR stimulation. We speculate that in this way Bcl
